Degron Therapeutics

Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list

Chinese biotech funding backed by venture capital and private equity firms experienced a much-needed uplift over the past few weeks, thanks partly to investor interest in assets with novel modalities

Who : AbbVie and Neomorph What: The two companies have signed a collaboration and option-to-license deal to develop molecular glue degraders in oncology and immunology. Why: The deal brings togeth

Takeda Pharmaceutical Co. Ltd. is the latest in a string of pharmaceutical manufacturers investing in molecular glue degraders through dealmaking. The company announced a collaboration with Shanghai-